Obesity
Not yet recruitingKAI-9531 in Adults With Obesity or Overweight and Diabetes
KAI-9531 in Adults With Obesity or Overweight and Diabetes
Hungary- Participants:18–64 years · 65+ years
- Substances:HRS 9531
- Sponsor:Kailera Therapeutics Inc.
Rare diseases
Investigational molecules
Locations
Back to Hungary650 clinical trials in Berettyoujfalu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.
KAI-9531 in Adults With Obesity or Overweight and Diabetes
HungaryA study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.
HungaryA study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis
HungaryStudy of telitacicept compared to placebo in adults with moderate to severe systemic lupus erythematosus
HungaryStudy of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)
HungaryStudy on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy
HungaryStudy of Avacopan Safety and Effectiveness in Patients with ANCA-associated Vasculitis
HungaryStudy on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults
HungaryStudy on Rocatinlimab for Adolescents Aged 12-17 with Moderate-to-Severe Atopic Dermatitis
HungaryStudy of LY3454738 for Treating Moderate-to-Severe Atopic Dermatitis in Adults
HungaryPhase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin
HungaryEfficacy and Safety of Fixed‑Dose Combination of Dapagliflozin, Bisoprolol Fumarate, and Eplerenone vs Usual Care in Hospitalized Acute Heart Failure Patients
HungaryThe busiest research cities in the country
What the registry says about research in the country
Innovative clinical trials focusing on primary prevention of atherosclerotic cardiovascular disease (ASCVD). The research examines advanced therapeutic approaches for reducing major adverse cardiovascular events in high-risk patients.
This groundbreaking research aims to evaluate new therapeutic strategies for improving cardiovascular outcomes in preventive cardiology, particularly focusing on patients who haven't yet experienced a cardiovascular event.
Tell us about your condition – we search every trial in Europe and connect you with the right site.